Original-Research: Marinomed Biotech AG (von First Berlin Equity Research Gmb...
^
Original-Research: Marinomed Biotech AG - from First Berlin Equity Research
GmbH
24.09.2026 / 17:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.
---------------------------------------------------------------------------
Classification of First Berlin Equity Research GmbH to Marinomed Biotech AG
Company Name: Marinomed Biotech AG
ISIN: ATMARINOMED6
Reason for the research: End of coverage
Recommendation: n.a.
from: 24.09.2026
Target price: n.a.
Target price on sight of: -
Last rating change: 24.09.2026, formerly Under Review
Analyst: Alexander Rihane
First Berlin Equity Research hat ein Research Update zu Marinomed Biotech AG
(ISIN: ATMARINOMED6) veröffentlicht. Analyst Alexander Rihane beendet die
Coverage der Aktie.
Zusammenfassung:
Nachdem Marinomed die erwarteten Meilensteinzahlungen von Unither
Pharmaceuticals nicht erhalten hatte, beantragte das Unternehmen am 22. Juli
eine gerichtlich betreute Sanierung. Heute stellte die Insolvenzverwalterin
Dr. Ulla Reisch einen Antrag auf Einstellung des Geschäftsbetriebs. Der
Antrag wurde angenommen, und das Insolvenzgericht ordnete die Einstellung
des Geschäftsbetriebs von Marinomed an. Dr. Ulla Reisch wird nun den Verkauf
der Vermögenswerte des Unternehmens einleiten. Wir beenden hiermit unsere
Coverage von Marinomed Biotech AG.
First Berlin Equity Research has published a research update on Marinomed
Biotech AG (ISIN: ATMARINOMED6). Analyst Alexander Rihane has ended his
coverage of the stock.
Abstract:
After not receiving anticipated milestone payments from Unither
Pharmaceuticals, Marinomed filed for court-administered restructuring on 22
July. Today, the insolvency administrator Dr. Ulla Reisch filed a motion to
close the business. The motion was accepted, and the insolvency court
ordered the closure of Marinomed's operations. Dr. Ulla Reisch will now
initiate a sale of the company's assets. We end our coverage of Marinomed
Biotech AG.
Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses
siehe die vollständige Analyse.
You can download the research here:
https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=64517f6d78673f8a9e50086b2a3da274
Contact for questions:
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com
---------------------------------------------------------------------------
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=bac38c21-b828-11f1-9d22-0a083a71a9ab&lang=en
---------------------------------------------------------------------------
2405102 24.09.2026 CET/CEST
°